{"database": "openregs", "table": "documents", "rows": [["EPA-HQ-OPP-2012-0565-0059", "EPA", "EPA-HQ-OPP-2012-0565", "Norflurazon: Responses to Additional Comments on the \u201cDraft Human Health Risk Assessment in Support of Registration Review, D432685\u201d Regarding Dermal Studies (June 12, 2019)", "Supporting & Related Material", "Comment Response", "2022-12-23T05:00:00Z", 2022, 12, null, null, "2022-12-24T01:48:32Z", null, 0, 0, "0900006485547dab"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["EPA-HQ-OPP-2012-0565-0059"], "units": {}, "query_ms": 5.10575994849205, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}